Answers are grounded in this paper and cite their sources.
Asthma is a common respiratory inflammatory condition, characterized by airway hyper-responsiveness, reversible constriction and structural remodelling.1 The prevalence of asthma is increasing and is estimated to affect more than 300 million people globally.1 Severe asthma can be defined as poor symptom control despite maximal inhaled therapy. 2 Severe asthma can affect children and adults and has significant morbidity, mortality and costs.1-3 Dysregulated type 2 (T2) immunity, characterized by interleukin (IL)-4, IL-5 and IL-13 signalling, immunoglobulin E (IgE) and eosinophilia, underlies most cases of asthma.4 Biological agents targeting IgE have existed for over a decade, and new biologics targeting T2 immunity are being developed.1 This Cochrane Corner evaluates and summarizes the safety and efficacy of biological therapies targeting IL-4 and IL-13 in moderate-to-severe asthma.
No takes yet. Share an insight, caveat, or question.
Boulton et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: